TCRX earnings: real EPS beat/miss history, analyst consensus Buy, P/E -0.94. Updated 2026-07-23.
TScan Therapeutics (TCRX) Research Hub
TScan Therapeutics (TCRX) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 0.3204 USD (-2.94%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -0.94, market cap 0.06B. This hub links to the full technical, earnings and options research available for TCRX.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 0.3204 USD (-2.94%) |
| 52-week range | 0.3055 USD – 1.26 USD |
| Trend regime | Range |
| 14-day RSI | 12.1 (Oversold) |
| Trailing P/E | -0.94 |
| Market cap | 0.06B |
| Dividend yield | 0.00% |
Available research for TCRX
Covered Call on TCRX: how it works, illustrative setup around the real 0.3204 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on TCRX: how it works, illustrative setup around the real 0.3204 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on TCRX: how it works, illustrative setup around the real 0.3204 USD price, max profit/loss, breakeven and when to use it. Educational.
TCRX technical analysis: range, last 0.3204 USD, RSI 12.1, 52w range 0.3055 USD–1.26 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is TCRX in?
TScan Therapeutics (TCRX) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is TCRX in an uptrend or downtrend?
As of 2026-09-11, TCRX is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is TCRX's trailing P/E ratio?
TCRX's trailing P/E is -0.94, with a market cap of 0.06B. See the earnings research page for full valuation detail.